SCHEMBL5147984

SCHEMBL5147984

Cn1nc(-c2nc(-c3ccccc3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.43
ALDH1A1 P00352 7/20 0.40
MAPT P10636 4/20 0.40
HTT P42858 1/20 0.40
FGFR1 P11362 2/20 0.40
CDK8 P49336 2/20 0.40
CSNK1A1 P48729 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
CSF1R P07333 1/20 0.40
FLT1 P17948 1/20 0.40
KDR P35968 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
CDK5 Q00535 1/20 0.40
PRKCQ Q04759 1/20 0.40
LRRK2 Q5S007 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
ADORA2A P29274 4/20 0.40
FGFR2 P21802 1/20 0.39
FGFR3 P22607 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152965 0.89 ADORA2A (0.47) BRD4ALDH1A1MAPTHTTFGFR1
SCHEMBL5152848 0.88 ALDH1A1 (0.41) BRD4ALDH1A1MAPTHTTFGFR1
SCHEMBL5149114 0.88 BRD4 (0.40) BRD4ALDH1A1MAPTHTTFGFR1
SCHEMBL5149132 0.87 ADORA2A (0.44) ALDH1A1MAPTADORA2AKDM4ESMN1; SMN2
SCHEMBL5149126 0.87 ALDH1A1 (0.42) BRD4ALDH1A1MAPTHTTADORA2A
SCHEMBL5148994 0.86 BRD4 (0.39) BRD4ALDH1A1MAPTHTTFGFR1
SCHEMBL5150667 0.86 POLB (0.40) BRD4ALDH1A1MAPTHTTFGFR1
SCHEMBL5147910 0.85 CDK8 (0.38) BRD4ALDH1A1MAPTHTTFGFR1
SCHEMBL5147917 0.85 ADORA2A (0.48) BRD4ALDH1A1MAPTHTTFGFR1
SCHEMBL5150645 0.85 ADORA2A (0.39) BRD4ALDH1A1MAPTHTTFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 BRD4 2661/4885ALDH1A1 748/4885MAPT 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.